Profile data is unavailable for this security.
About the company
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
- Revenue in CAD (TTM)12.27bn
- Net income in CAD-622.53m
- Incorporated2013
- Employees20.27k
- LocationBausch Health Companies Inc2150 St. Elzear Blvd. West, LavalLAVAL H7L 4A8CanadaCAN
- Phone+1 (514) 744-6792
- Fax+1 (514) 744-6792
- Websitehttps://www.bauschhealth.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Dubl-Crne Phrmctl Co Ltd | 1.95bn | 260.09m | 3.57bn | 12.27k | 13.54 | 1.62 | -- | 1.83 | 1.34 | 1.34 | 10.07 | 11.24 | 0.6781 | 2.85 | 5.82 | 841,054.60 | 8.87 | 8.58 | 11.67 | 11.21 | 54.25 | 58.19 | 13.08 | 11.98 | 2.15 | -- | 0.0249 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Suven Pharmaceuticals Ltd | 172.45m | 49.25m | 3.64bn | 1.05k | 73.89 | 10.83 | 62.57 | 21.12 | 11.81 | 11.81 | 41.34 | 80.56 | 0.4983 | 1.64 | 8.58 | 9,993,856.00 | 14.23 | 23.17 | 15.19 | 26.20 | 57.34 | 58.85 | 28.56 | 33.21 | 9.64 | 47.59 | 0.0307 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Tasly Pharmaceutical Group Co Ltd | 1.63bn | 207.85m | 3.66bn | 9.22k | 17.68 | 1.53 | -- | 2.24 | 0.7342 | 0.7342 | 5.77 | 8.47 | 0.4899 | 1.72 | 10.80 | 937,046.80 | 5.93 | 5.47 | 7.21 | 7.25 | 65.67 | 48.42 | 12.11 | 8.94 | 2.73 | 5.91 | 0.2083 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| Natco Pharma Ltd. | 655.92m | 227.72m | 3.70bn | 3.98k | 16.30 | 3.85 | 14.33 | 5.65 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Joincare Pharmaceutical Group Ind. Co. | 3.10bn | 268.24m | 3.77bn | 14.37k | 13.86 | 1.40 | -- | 1.21 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Bausch Health Companies Inc | 12.27bn | -622.53m | 3.77bn | 20.27k | -- | -- | 3.51 | 0.3075 | -1.70 | -1.70 | 33.49 | -4.16 | 0.3425 | 1.83 | 4.80 | 605,193.90 | -1.83 | -2.74 | -2.27 | -3.31 | 70.81 | 71.59 | -5.34 | -9.78 | 0.8536 | 1.19 | 1.01 | -- | 7.79 | 0.884 | -163.11 | -- | 2.97 | -- |
| Pfizer Ltd | 359.74m | 90.43m | 3.82bn | 1.70k | 42.19 | 6.47 | 37.90 | 10.60 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Bora Pharmaceuticals Co Ltd | 514.13m | 113.36m | 3.91bn | 91.00 | 35.12 | 10.69 | 27.16 | 7.60 | 26.17 | 26.17 | 117.72 | 85.94 | 0.4592 | 2.73 | 2.73 | -- | 10.37 | 11.27 | 20.97 | 18.66 | 53.53 | 39.25 | 22.58 | 18.55 | 1.03 | 4.55 | 0.4411 | 37.82 | 35.31 | 59.57 | 117.70 | 46.91 | 128.20 | 64.83 |
| Laurus Labs Ltd | 826.84m | 26.33m | 4.04bn | 6.01k | 153.72 | 5.99 | 44.57 | 4.89 | 2.97 | 2.97 | 93.32 | 76.27 | 0.6282 | 1.38 | 3.11 | 8,391,593.00 | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 47.63 | 3.34 | 12.83 | 0.6393 | 2.22 | 0.3851 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
